EirGenix (TPE:6589) has submitted a marketing authorization application to the European Medicines Agency for EG1206A, a pertuzumab biosimilar, according to a Wednesday filing with the Taiwan Stock Exchange.
The drug is is intended for the treatment of HER2-positive early breast cancer and metastatic breast cancer.
Earlier this year, EirGenix and commercialization partner Sandoz entered into a settlement and patent license agreement with Genentech and Roche for the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.